Wolfgang Miesbach: Base Editing and the Future of Sickle Cell Disease Therapy
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Base editing. Gene editing 2.0?
At EHA 2026, Maria Morelló Miravet (Karolinska Institutet, Stockholm) showed how precise base editing of hematopoietic stem cells (HSCs) can move from concept to clinic in sickle cell disease (SCD):
Unlike classical CRISPR‑Cas9 nucleases that rely on double‑strand breaks and stochastic indels, base editors convert single nucleotides at predefined sites using deaminases fused to a Cas9 nickase.
This enables highly controlled editing of regulatory elements such as HBG promoters or BCL11A‑related loci, with the goal of re‑inducing fetal hemoglobin (HbF) while limiting chromosomal rearrangements and p53‑mediated stress responses.
This presentation is a powerful reminder that academia can drive first‑in‑class, highly sophisticated innovative programs, from basic biology and manufacturing to regulatory strategy and clinical implementation ”
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Jun 15, 2026, 13:22Debra BenAvram: Every Two Seconds – Someone Needs Blood
-
Jun 15, 2026, 13:13Christina Ornauer: Exploring the Latest Advances in Hematology at EHA 2026
-
Jun 15, 2026, 13:05Angelo Zanniti: Back from EHA 2026 Congress
-
Jun 15, 2026, 12:56Chiara Pirillo: Building Global Connections at EHA 2026
-
Jun 15, 2026, 12:50Marina Planas: MRD and Molecular Monitoring Take Center Stage at EHA 2026
-
Jun 15, 2026, 12:46Moonmoon Kazi: Climb Bio Presents Phase 1b ITP Trial Data at EHA 2026
-
Jun 15, 2026, 12:31Chandrashekhar Athare: EHA 2026 Concludes with Lasting Impact and New Collaborations
-
Jun 15, 2026, 10:49Aurelio Maggio: How Is The Treatment Landscape Of Thrombotic Thrombocytopenic Purpura Evolving?
-
Jun 15, 2026, 10:49Marek Mráz: A Landmark EHA 2026 for Our Lab